Results 221 to 230 of about 4,195,887 (419)

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source

Confirmatory Factor Analysis of the School Refusal Assessment Scale-Revised in an African American Community Sample [PDF]

, 2009
Aaron R. Lyon
openalex   +1 more source

Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance

Molecular Oncology, EarlyView.
Cellular heterogeneity is a major cause of drug resistance in cancer. Segeren et al. used single‐cell transcriptomics to investigate gene expression events that correlate with sensitivity to the DNA‐damaging drugs gemcitabine and prexasertib. They show that dampened expression of transcription factor FOXM1 and its target genes protected cells against ...
Hendrika A. Segeren, Kathryn A. Wierenga, Frank M. Riemers, Elsbeth A. van Liere, Bart Westendorp   +4 more
wiley   +1 more source

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

Molecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh, Amelia Martinez Villarreal, Philippe Lefrançois, Jennifer Gantchev, Sriraam Sivachandran, Samy Abou Setah, Ivan V. Litvinov   +6 more
wiley   +1 more source

The Medication-Related Burden Quality of Life (MRB-QoL) tool: A confirmatory factor analysis of the Arabic version. [PDF]

Explor Res Clin Soc Pharm
Al-Ebrahim SQ, Hafidh K, Jallo M, Mauwfak MM, Nassef M, Alzubaidi H, Harrison J, Chen TF, Mohammed MA.   +8 more
europepmc   +1 more source

Employers' Perception and Practice of Workplace Violence Prevention at Healthcare Facilities Questionnaire: A Confirmatory Factor Analysis. [PDF]

Malays J Med Sci, 2023
Mohamad Yazid MN, Nik Husain NR, Daud A, Osman Y, Mustapa N, Abdul Hadi A.   +5 more
europepmc   +1 more source

Construct Validity of the Korean Dental Licensing Examination using Confirmatory Factor Analysis

, 2005
Mi Kyoung Yim, Yoon Hee Kim
openalex   +1 more source

Recovery of weak factor loadings in confirmatory factor analysis under conditions of model misspecification [PDF]

, 2009
Carmen Ximénez
openalex   +1 more source

CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR‐15b‐5p and miR‐7‐1‐3p processing in nasopharyngeal carcinoma

Molecular Oncology, EarlyView.
CircCCNB1 expression is down‐regulated in nasopharyngeal carcinoma (NPC); thus, less NF90 protein is bound to circCCNB1 and more binds to pri‐miRNAs, blocking their (pri‐miRNAs) binding to DGCR8 and inhibiting the processing and generation of miR‐15b‐5p/miR‐7‐1‐3p. Furthermore, decreased miR‐15b‐5p/miR‐7‐1‐3p promotes the expression of the target genes
Chunmei Fan, Fenghua Tan, Jie Wu, Zhaoyang Zeng, Wenjia Guo, He Huang, Wei Xiong   +6 more
wiley   +1 more source

Psychometric properties of the Swedish version of the Patient Health Questionnaire-9: an investigation using Rasch analysis and confirmatory factor analysis. [PDF]

BMC Psychiatry
Forsström D, Badinlou F, Johansson M, Ojala O, Alaoui SE, Månsson KNT, Rozental A, Lundin J, Jangard S, Shahnavaz S, Sörman K, Jayaram-Lindström N, Lundgren T, Jansson-Fröjmark M, Hedman-Lagerlöf M.   +14 more
europepmc   +1 more source